135 results on '"Horie, Yoshiki"'
Search Results
2. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
3. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
4. Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
5. Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers
6. Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study
7. Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.
8. Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.
9. MO19-3 Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy
10. MO18-6 Predictive value of CDC37 gene expression for regorafenib in metastatic colorectal cancer (mCRC)
11. Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
12. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
13. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy
14. Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer
15. Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407.
16. MO35-2 Symptom monitoring and its digitalization at daily cancer chemotherapy in Japan: a nation-wide multi-stakeholder survey
17. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
18. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling
19. The utility of G8 screening for clinical practice of chemotherapy in older patients with gastrointestinal cancer
20. Efficacy and safety of neoadjuvant chemotherapy for locally advanced gastric cancer in elderly patients: A phase II trial (KSCC1801).
21. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.
22. The Feasibility of Edoxaban for Asymptomatic Cancer-associated Thrombosis in Japanese Gastrointestinal Cancer Patients (ExCAVE study)
23. Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis
24. MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients
25. P29-4 An exploratory study of challenges to delivering palliative care from the time of cancer diagnosis
26. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study
27. P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients
28. Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data.
29. Barriers to and facilitators of implementation of the integration of oncology and palliative care in daily practice: a systematic review
30. Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment
31. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial.
32. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report
33. Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment.
34. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
35. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
36. Current status of integrating oncology and palliative care in Japan: A nationwide survey
37. Current status of integrating oncology and palliative care in Japan: A nationwide survey
38. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients
39. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy
40. Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer
41. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
42. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer
43. Perspectives and attitudes toward the integration of oncology and palliative care in Japan: Qualitative analysis of a nationwide survey.
44. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
45. Phase III Study Of Comparing Dexamethasone On Day 1 With Day 1-4 With Combined Neurokinin-1 Receptor Antagonist, Palonosetron And Olanzapine In Cisplatin-Based Chemotherapy : Spared Trial
46. Abstract CT052: Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
47. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
48. Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
49. Abstract 3818: Identification of aFGFR3-TACC3fusion in esophageal cancer
50. Dose finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer: The initial safety analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.